Lmr Partners LLP Sarepta Therapeutics, Inc. Call Options Transaction History

Lmr Partners LLP

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 07, 2024	SELL	$124.33 - $156.75 $3.99 Million - $5.03 Million	-32,100 Reduced 46.45%	37,000 $4.62 Million
Q2 2024 Aug 14, 2024	SELL	$113.33 - $163.85 $3.83 Million - $5.54 Million	-33,800 Reduced 32.85%	69,100 $10.9 Million
Q1 2024 May 15, 2024	SELL	$93.7 - $141.53 $8.53 Million - $12.9 Million	-91,000 Reduced 46.93%	102,900 $13.3 Million
Q4 2023 Feb 14, 2024	BUY	$67.31 - $124.76 $592,328 - $1.1 Million	8,800 Added 4.75%	193,900 $18.7 Million
Q3 2023 Nov 14, 2023	SELL	$102.5 - $123.59 $3.57 Million - $4.3 Million	-34,800 Reduced 15.83%	185,100 $22.4 Million
Q2 2023 Aug 14, 2023	BUY	$106.4 - $157.19 $23.4 Million - $34.6 Million	219,900 New	219,900 $25.2 Million

532

84.5M

2.06M

1.52M

Ticker SRPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,567,904
Market Cap $9.15B
Description
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...

Get notified when there are updates to the investment portfolio of Lmr Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Lmr Partners LLP with notifications on news.